Dipexium Pharma (DPRX) Halted LUDP
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Equities mixed as investors eye earnings; yen on intervention watch
- ServiceNow (NOW) stock falls as refreshed subscription outlook trails estimates
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Dipexium Pharma (DPRX) Resumes Trading Following LUDP Halt
October 25, 2016 12:35 PM EDTDipexium Pharma (NASDAQ: DPRX) resumed trading after LUDP halt. Shares last down 76.5%, versus down 74% prior to halt.
... MoreFeltl & Co Downgrades Dipexium Pharmaceuticals (DPRX) to Hold
October 25, 2016 11:52 AM EDTFeltl & Co downgraded Dipexium Pharmaceuticals (NASDAQ: DPRX) from Buy to Hold.
For an analyst ratings summary and ratings history on Dipexium Pharmaceuticals click here. For more ratings news on Dipexium Pharmaceuticals click here.
Shares of Dipexium Pharmaceuticals closed at $12.75 yesterday.
... MorePre-Open Stock Movers 10/25: (SAEX) (CWEI) (SWFT) Higher; (DPRX) (CRBP) (UA) Lower (more...)
October 25, 2016 9:05 AM EDTPre-Open Stock Movers
Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX) 84.7% LOWER; announced that the OneStep-1 and OneStep-2 Phase 3 clinical trials of Locilex (pexiganan cream 0.8%) in patients with mild infections of diabetic foot ulcers (Mild DFI) did not meet the primary clinical endpoint of superiority versus vehicle plus standardized wound care and also did not show any meaningful difference in wound closure rate between the Locilex arm and the vehicle arm in each study. Neither trial met the secondary endpoint of demonstrating a higher rate of eradication of bacteria for the... More
Dipexium Pharma (DPRX) will resume trading at 7:30am ET
October 25, 2016 7:11 AM EDTDipexium Pharma (Nasdaq: DPRX) will resume trading at 7:30am EDT.
... MoreDipexium Pharma (DPRX) Announces Locilex Phase 3s Missed Primary Endpoints
October 25, 2016 7:04 AM EDTDipexium Pharmaceuticals, Inc. (Nasdaq: DPRX) announced that the OneStep-1 and OneStep-2 Phase 3 clinical trials of Locilex (pexiganan cream 0.8%) in patients with mild infections of diabetic foot ulcers (Mild DFI) did not meet the primary clinical endpoint of superiority versus vehicle plus standardized wound care and also did not show any meaningful difference in wound closure rate between the Locilex arm and the vehicle arm in each study. Neither trial met the secondary endpoint of demonstrating a higher rate of eradication of bacteria for the Locilex arm. While the overall adverse event incidence was comparable... More
Dipexium Pharma (DPRX) trading halted with news pending
October 25, 2016 6:56 AM EDTDipexium Pharma (NASDAQ: DPRX) trading halted with news pending.
... More
